REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

18/06/2020 12:25

RNS Number : 4041Q
  
GlaxoSmithKline PLC
  
18 June 2020
  
 

GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Waterhouse 




b)


Position/status


CEO of ViiV Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


Following the final vesting on 15 June 2020 of an award made on 15 June 2017 under the GlaxoSmithKline Deferred Investment Award programme, Ms Waterhouse will receive a cash payment of £75,564.47 less applicable tax withholding in respect of 4,720.419 notional Ordinary Shares. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


16.008


4,720.419


 




 


 


 


 




d)


Aggregated information
 
 


N/A (single transaction) 




Aggregated volume Price


 




e)


Date of the transaction


2020-06-15




f)


Place of the transaction
 


N/A




 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHFVLFFBQLLBBX